BMKGENE provided long non-coding RNA sequencing services for the article “The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis”, which was published in Biomaterials, herein, an OCs’ microenvironment-responsive nanoplatform-HMCZP is developed.
The study shows that HMCZP is more effective in inhibiting mature OCs activity and reversing systemic bone loss in ovariectomized mice compared to the first-line therapy. High-throughput RNA sequencing (RNA-seq) revealed that HMCZP could down-regulate a critical target for osteoporosis, tartrate-resistant acid phosphatase (TRAP), and other potential therapeutic targets. These findings suggest that using an intelligent nanoplatform that targets OCs is a promising strategy for osteoporosis therapy.
Click here to learn more about this study.
Post time: Dec-20-2023